3.93

5.36% 0.20

Personalis Inc (PSNL)

Overview News Price History Option Chain Financials Discussions Forecast

Personalis Inc stock is traded at $3.93, with a volume of 949.11K. It is up +5.36% in the last 24 hours and down -16.56% over the past month. Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Previous Close:

$3.73

Open:

$3.73

24h Volume:

949.11K

Relative Volume:

1.21

Market Cap:

$275.17M

Revenue:

$73.48M

Net Income/Loss:

$-108.30M

P/E Ratio:

-1.6653

EPS:

-2.36

Net Cash Flow:

$-67.17M

1W Performance:

+13.58%

1M Performance:

-16.56%

6M Performance:

+193.28%

1Y Performance:

+118.33%

1-Day Range:

$3.73

$4.18

1-Week Range:

$3.28

$4.18

52-Week Range:

$1.12

$7.20

Personalis Inc Stock (PSNL) Company Profile

Name

Personalis Inc

Sector

Healthcare (1200)

Industry

Diagnostics & Research (57)

Phone

650-752-1300

Address

6600 DUMBARTON CIRCLE, FREMONT, CA

Employee

225

Twitter

@PersonalisInc

Next Earnings Date

2024-11-06

Latest SEC Filings

PSNL's Discussions on Twitter

Compare PSNL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PSNL Personalis Inc	3.93	275.17M	73.48M	-108.30M	-67.17M	-2.36
TMO Thermo Fisher Scientific Inc	521.66	199.82B	42.37B	6.14B	7.78B	15.26
DHR Danaher Corp	238.83	173.66B	23.74B	3.89B	4.98B	7.93
A Agilent Technologies Inc	138.14	38.64B	6.51B	1.29B	1.37B	3.82
IQV Iqvia Holdings Inc	201.43	36.52B	15.32B	1.41B	1.96B	5.95
IDXX Idexx Laboratories Inc	421.76	34.55B	3.84B	866.24M	792.60M	9.80

Personalis Inc Stock (PSNL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-06-23	Upgrade	Needham	Hold → Buy
Jan-07-22	Upgrade	BofA Securities	Neutral → Buy
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-03-21	Downgrade	Needham	Buy → Hold
Oct-15-21	Resumed	Cowen	Outperform
Sep-20-21	Reiterated	Needham	Buy
May-06-21	Upgrade	Oppenheimer	Perform → Outperform
Jan-28-21	Initiated	Truist	Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Nov-12-20	Reiterated	Needham	Buy
Nov-06-20	Downgrade	Oppenheimer	Outperform → Perform
Oct-19-20	Initiated	Citigroup	Buy
Oct-08-20	Initiated	BTIG Research	Buy
Aug-27-20	Initiated	H.C. Wainwright	Buy
Aug-18-20	Initiated	Needham	Buy
Sep-26-19	Upgrade	BofA/Merrill	Neutral → Buy
Jul-15-19	Initiated	BofA/Merrill	Neutral
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Morgan Stanley	Overweight
Jul-15-19	Initiated	Oppenheimer	Outperform

View All

Personalis Inc Stock (PSNL) Latest News

Nov 22, 2024

Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.

Nov 22, 2024

Nov 21, 2024

Personalis CFO Aaron Tachibana sells $4,953 in stock By Investing.com - Investing.com Australia

Nov 21, 2024

Personalis to Participate at Upcoming Investor Conferences - The Bakersfield Californian

Nov 20, 2024

Nov 19, 2024

Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St

Nov 19, 2024

Personalis, Inc. (NASDAQ:PSNL) Shares Sold by GSA Capital Partners LLP - MarketBeat

Nov 19, 2024

Nov 13, 2024